Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ip CLC"'
Autor:
Graham R. Foster, A da Silva Filipe, John McLauchlan, A Ansari, William L. Irving, V Pedergnana, Connor G. G. Bamford, Eleanor Barnes, Paul Klenerman, Rory Bowden, L S Hin, Spencer Cca., Amy Trebes, Vanessa M. Cowton, Elihu Aranday-Cortes, Arvind H. Patel, Christopher Holmes, Emma Hudson, Kosh Agarwal, E. Thomson, Peter Simmonds, Ip Clc., Vattipally B. Sreenu, Paolo Piazza, David Bonsall
Type III interferons (IFN-λ) are part of the innate immune response to hepatitis C virus (HCV) infection however the specific role of IFN-λ4 and the nature of the viral adaption to this pressure have not been defined. Here we use paired genome-wide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9629832809174165f7287955dc8a266b
Autor:
Tongai Maponga, Anna L McNaughton, M de Cesare, Philippa C Matthews, Richard H. Glashoff, David Bonsall, Wolfgang Preiser, Ip Clc., Monique Andersson, M A Ansari
Publikováno v:
Journal of Hepatology. 70:e709-e710
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80666b031c4ace85152a48187866b17d
https://doi.org/10.1016/s0618-8278(19)31417-3
https://doi.org/10.1016/s0618-8278(19)31417-3
Autor:
David A. Smith, Andrea Magri, Rory Bowden, David Bonsall, Peter Simmonds, Anthony Brown, Eleanor Barnes, Ip Clc., Paolo Piazza, M A Ansari, D Nguyen, Amy Trebes
Publikováno v:
Hepatology (Baltimore, Md.)
Hepatitis C virus (HCV) genotype (gt) 3 is highly prevalent globally, with non-gt3a subtypes common in Southeast Asia. Resistance-associated substitutions (RASs) have been shown to play a role in treatment failure. However, the role of RASs in gt3 is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5db3901ea549eb24c8ec6a234797fbb7
https://pubmed.ncbi.nlm.nih.gov/29425396
https://pubmed.ncbi.nlm.nih.gov/29425396
Autor:
Thomson, E, Ip, CLC, Badhan, A, Christiansen, MT, Adamson, W, Ansari, MA, Bibby, D, Breuer, J, Brown, A, Bowden, R, Bryant, J, Bonsall, D, Da Silva Filipe, A, Hinds, C, Hudson, E, Klenerman, P, Lythgow, K, Mbisa, JL, McLauchlan, J, Myers, R, Piazza, P, Roy, S, Trebes, A, Sreenu, VB, Witteveldt, J, Barnes, E, Simmonds, P
Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV) may potentially identify both viral genotype and resistance genetic motifs in the era of directly acting antiviral (DAA) therapies. This study compared the ability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c708550bcf0abafaf93cfea5121b0ac6
https://doi.org/10.1128/jcm.00330-16
https://doi.org/10.1128/jcm.00330-16
Autor:
Daniel J. Wilson, Ip Clc., Angela Kearns, N C Gordon, Anne-Sophie Walker, Elizabeth M. Batty, Mark H. Wilcox, Peto Tea., R Lay, Peter Donnelly, Lily O’Connor, John E. Paul, Xavier Didelot, Rory Bowden, David Buck, Paolo Piazza, David W Eyre, Derrick W. Crook, Tanya Golubchik, A Shaw
Publikováno v:
BMJ Open
Objectives To investigate the prospects of newly available benchtop sequencers to provide rapid whole-genome data in routine clinical practice. Next-generation sequencing has the potential to resolve uncertainties surrounding the route and timing of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd84a50f25aec4413c3bafd024edf2b8
https://doi.org/10.1136/bmjopen-2012-001124
https://doi.org/10.1136/bmjopen-2012-001124
Autor:
Elizabeth M. Batty, Paolo Piazza, Daniel J. Wilson, David W Eyre, Peto Tea., Derrick W. Crook, AS Walker, Xavier Didelot, Madeleine Cule, Ip Clc., Mark H. Wilcox, David J. Griffiths, Alison Vaughan, Tanya Golubchik, John Finney, Kate E. Dingle, Lily O’Connor, Rory Bowden, David H. Wyllie, Rosalind M. Harding
BACKGROUND: It has been thought that Clostridium difficile infection is transmitted predominantly within health care settings. However, endemic spread has hampered identification of precise sources of infection and the assessment of the efficacy of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e92020e8f308bcff549cc2c023e885
https://ora.ox.ac.uk/objects/uuid:87338811-cc57-4540-a127-8452cebe1e00
https://ora.ox.ac.uk/objects/uuid:87338811-cc57-4540-a127-8452cebe1e00
Autor:
Ip, CLC, Ansari, MA, Brown, A, Bowden, R, Bonsall, D, Hudson, E, Klenerman, P, Piazza, P, Trebes, A, Barnes, E, Simmonds, P, STOP-HCV Consortium
Publikováno v:
Journal of Clinical Microbiology. 54(10)
Affordable next generation sequencing (NGS) technologies for hepatitis C virus (HCV) may potentially identify both viral genotype and resistance genetic motifs in the era of directly acting anti-viral (DAA) therapies. This study compared the ability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::9f2cf15524a9a601659319609e445cf1
http://ora.ox.ac.uk/objects/uuid:11a2d9c8-3203-4444-81e8-9ccc67ddc061
http://ora.ox.ac.uk/objects/uuid:11a2d9c8-3203-4444-81e8-9ccc67ddc061
Autor:
Manso CF; Public Health England, London, United Kingdom., Bibby DF; Public Health England, London, United Kingdom., Lythgow K; Public Health England, London, United Kingdom., Mohamed H; Public Health England, London, United Kingdom., Myers R; Public Health England, London, United Kingdom., Williams D; Public Health England, London, United Kingdom., Piorkowska R; Public Health England, London, United Kingdom., Chan YT; Public Health England, London, United Kingdom., Bowden R; The Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom., Ansari MA; The Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.; Peter Medawar Building for Pathogen Research and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Ip CLC; The Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom., Barnes E; Peter Medawar Building for Pathogen Research and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Bradshaw D; Public Health England, London, United Kingdom., Mbisa JL; Public Health England, London, United Kingdom.; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections, London, United Kingdom.
Publikováno v:
Frontiers in microbiology [Front Microbiol] 2020 Oct 09; Vol. 11, pp. 576572. Date of Electronic Publication: 2020 Oct 09 (Print Publication: 2020).
Autor:
Smith D; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK., Magri A; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.; Oxford Martin School, University of Oxford, Oxford, UK., Bonsall D; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Ip CLC; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Trebes A; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Brown A; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK., Piazza P; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Bowden R; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Nguyen D; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK., Ansari MA; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.; Oxford Martin School, University of Oxford, Oxford, UK., Simmonds P; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK., Barnes E; Nuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, UK.
Publikováno v:
Hepatology (Baltimore, Md.) [Hepatology] 2019 May; Vol. 69 (5), pp. 1861-1872. Date of Electronic Publication: 2018 Apr 27.
Autor:
Bowden R; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Davies RW; Genomics plc, Oxford, OX1 1JD, UK.; Program in Genetics and Genomic Biology and The Centre for Applied Genomics, Hospital for Sick Children, Toronto, M5G 0A4, Canada., Heger A; Genomics plc, Oxford, OX1 1JD, UK., Pagnamenta AT; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.; National Institute for Health Research Oxford Biomedical Research Centre, Oxford, OX4 2PG, UK., de Cesare M; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Oikkonen LE; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Parkes D; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Freeman C; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Dhalla F; Department of Clinical Immunology, Oxford University Hospitals, Oxford, OX3 9DU, UK.; Developmental Immunology Group, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK., Patel SY; Department of Clinical Immunology, Oxford University Hospitals, Oxford, OX3 9DU, UK.; Clinical Immunology Group, National Institute for Health Research Oxford Biomedical Research Centre, Oxford, OX4 2PG, UK., Popitsch N; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.; National Institute for Health Research Oxford Biomedical Research Centre, Oxford, OX4 2PG, UK.; Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, 1090, Vienna, Austria., Ip CLC; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Roberts HE; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Salatino S; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Lockstone H; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Lunter G; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.; Genomics plc, Oxford, OX1 1JD, UK., Taylor JC; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.; National Institute for Health Research Oxford Biomedical Research Centre, Oxford, OX4 2PG, UK., Buck D; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK., Simpson MA; Genomics plc, Oxford, OX1 1JD, UK., Donnelly P; Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK. donnelly@well.ox.ac.uk.; Genomics plc, Oxford, OX1 1JD, UK. donnelly@well.ox.ac.uk.; Department of Statistics, University of Oxford, Oxford, OX1 3LB, UK. donnelly@well.ox.ac.uk.
Publikováno v:
Nature communications [Nat Commun] 2019 Apr 23; Vol. 10 (1), pp. 1869. Date of Electronic Publication: 2019 Apr 23.